Cargando…
Traditional Chinese medicine for pulmonary fibrosis therapy: Progress and future prospects
ETHNOPHARMACOLOGICAL RELEVANCE: Pulmonary fibrosis (PF) is a chronic, debilitating and often lethal lung disorder. Despite the molecular mechanisms of PF are gradually clear with numerous researchers’ efforts, few effective drugs have been developed to reverse human PF or even halt the chronic progr...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Ireland Ltd.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7127743/ https://www.ncbi.nlm.nih.gov/pubmed/28038955 http://dx.doi.org/10.1016/j.jep.2016.12.042 |
_version_ | 1783516425879552000 |
---|---|
author | Li, Liu-Cheng Kan, Lian-Di |
author_facet | Li, Liu-Cheng Kan, Lian-Di |
author_sort | Li, Liu-Cheng |
collection | PubMed |
description | ETHNOPHARMACOLOGICAL RELEVANCE: Pulmonary fibrosis (PF) is a chronic, debilitating and often lethal lung disorder. Despite the molecular mechanisms of PF are gradually clear with numerous researchers’ efforts, few effective drugs have been developed to reverse human PF or even halt the chronic progression to respiratory failure. Traditional Chinese medicine (TCM), the main component of the medical practice used for more than 5000 years especially in China, often exerts wider action spectrum than previously attempted options in treating human diseases. Recent data have shown the anti-fibrotic benefits of the active ingredients from TCM in this field, which may represent an attractive source of the drug discovery against PF. AIM OF THE REVIEW: This review summarizes the pre-clinical and clinical evidence on the benefits of TCM and their active ingredients, and provides a comprehensive information and reliable basis for the exploration of new treatment strategies of botanical drugs in the therapy of PF. METHODS: The literature information was obtained from the scientific databases on ethnobotany and ethno medicines (up to Aug 2016), mainly from the Pubmed, Web of Science and CNKI databases, and was to identify the experimental studies on the anti-fibrotic role of the active agents from TCM and the involved mechanisms. The search keywords for such work included: “lung fibrosis” or “pulmonary fibrosis”, and “traditional Chinese medicine”, “extract” or “herb”. RESULTS: A number of studies have shown that the active agents of single herbs and TCM formulas, particularly the flavonoids, glycosides and alkaloids, exhibit potential benefits against PF, the mechanisms of which appear to involve the regulation of inflammation, oxidant stress, and pro-fibrotic signaling pathways, etc. Besides, the processing methods for discovering TCM in treating PF were prospectively discussed. CONCLUSION: These research work have shown the therapeutic benefits of TCM in the treatment of PF. However, more continued researches should be undertaken to clarify the unconfirmed chemical composition and regulatory mechanisms, conduct standard clinical trials, and evaluate the possible side effects. The insights provided in present review will be needed for further exploration of botanical drugs in the development of PF therapy. |
format | Online Article Text |
id | pubmed-7127743 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Elsevier Ireland Ltd. |
record_format | MEDLINE/PubMed |
spelling | pubmed-71277432020-04-08 Traditional Chinese medicine for pulmonary fibrosis therapy: Progress and future prospects Li, Liu-Cheng Kan, Lian-Di J Ethnopharmacol Article ETHNOPHARMACOLOGICAL RELEVANCE: Pulmonary fibrosis (PF) is a chronic, debilitating and often lethal lung disorder. Despite the molecular mechanisms of PF are gradually clear with numerous researchers’ efforts, few effective drugs have been developed to reverse human PF or even halt the chronic progression to respiratory failure. Traditional Chinese medicine (TCM), the main component of the medical practice used for more than 5000 years especially in China, often exerts wider action spectrum than previously attempted options in treating human diseases. Recent data have shown the anti-fibrotic benefits of the active ingredients from TCM in this field, which may represent an attractive source of the drug discovery against PF. AIM OF THE REVIEW: This review summarizes the pre-clinical and clinical evidence on the benefits of TCM and their active ingredients, and provides a comprehensive information and reliable basis for the exploration of new treatment strategies of botanical drugs in the therapy of PF. METHODS: The literature information was obtained from the scientific databases on ethnobotany and ethno medicines (up to Aug 2016), mainly from the Pubmed, Web of Science and CNKI databases, and was to identify the experimental studies on the anti-fibrotic role of the active agents from TCM and the involved mechanisms. The search keywords for such work included: “lung fibrosis” or “pulmonary fibrosis”, and “traditional Chinese medicine”, “extract” or “herb”. RESULTS: A number of studies have shown that the active agents of single herbs and TCM formulas, particularly the flavonoids, glycosides and alkaloids, exhibit potential benefits against PF, the mechanisms of which appear to involve the regulation of inflammation, oxidant stress, and pro-fibrotic signaling pathways, etc. Besides, the processing methods for discovering TCM in treating PF were prospectively discussed. CONCLUSION: These research work have shown the therapeutic benefits of TCM in the treatment of PF. However, more continued researches should be undertaken to clarify the unconfirmed chemical composition and regulatory mechanisms, conduct standard clinical trials, and evaluate the possible side effects. The insights provided in present review will be needed for further exploration of botanical drugs in the development of PF therapy. Elsevier Ireland Ltd. 2017-02-23 2016-12-28 /pmc/articles/PMC7127743/ /pubmed/28038955 http://dx.doi.org/10.1016/j.jep.2016.12.042 Text en © 2016 Elsevier Ireland Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Article Li, Liu-Cheng Kan, Lian-Di Traditional Chinese medicine for pulmonary fibrosis therapy: Progress and future prospects |
title | Traditional Chinese medicine for pulmonary fibrosis therapy: Progress and future prospects |
title_full | Traditional Chinese medicine for pulmonary fibrosis therapy: Progress and future prospects |
title_fullStr | Traditional Chinese medicine for pulmonary fibrosis therapy: Progress and future prospects |
title_full_unstemmed | Traditional Chinese medicine for pulmonary fibrosis therapy: Progress and future prospects |
title_short | Traditional Chinese medicine for pulmonary fibrosis therapy: Progress and future prospects |
title_sort | traditional chinese medicine for pulmonary fibrosis therapy: progress and future prospects |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7127743/ https://www.ncbi.nlm.nih.gov/pubmed/28038955 http://dx.doi.org/10.1016/j.jep.2016.12.042 |
work_keys_str_mv | AT liliucheng traditionalchinesemedicineforpulmonaryfibrosistherapyprogressandfutureprospects AT kanliandi traditionalchinesemedicineforpulmonaryfibrosistherapyprogressandfutureprospects |